TMC Life Sciences Berhad Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for TMC Life Sciences Berhad.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Healthcare kazanç büyümesi	2.4%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

TMC Life Sciences Berhad (KLSE:TMCLIFE) Seems To Use Debt Quite Sensibly

Feb 14

We Think TMC Life Sciences Berhad (KLSE:TMCLIFE) Can Stay On Top Of Its Debt

Sep 29

Investors Met With Slowing Returns on Capital At TMC Life Sciences Berhad (KLSE:TMCLIFE)

Aug 26

TMC Life Sciences Berhad (KLSE:TMCLIFE) Shareholders Will Want The ROCE Trajectory To Continue

May 26

TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Feb 09

Returns On Capital - An Important Metric For TMC Life Sciences Berhad (KLSE:TMCLIFE)

Jan 13

Would Shareholders Who Purchased TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Three Years Be Happy With The Share price Today?

Dec 22

Should You Use TMC Life Sciences Berhad's (KLSE:TMCLIFE) Statutory Earnings To Analyse It?

Dec 02

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak TMC Life Sciences Berhad yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

KLSE:TMCLIFE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (MYR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	346	41	46	75	N/A
3/31/2024	357	53	65	100	N/A
12/31/2023	353	57	68	97	N/A
9/30/2023	332	48	41	73	N/A
6/30/2023	312	39	20	55	N/A
3/31/2023	298	49	3	52	N/A
12/31/2022	277	42	-11	45	N/A
9/30/2022	263	44	-18	52	N/A
6/30/2022	244	41	-33	36	N/A
3/31/2022	226	22	-47	-1	N/A
12/31/2021	213	18	-71	-1	N/A
9/30/2021	203	17	-87	-1	N/A
6/30/2021	201	20	-81	22	N/A
6/30/2020	184	16	-146	18	N/A
5/31/2020	190	10	-139	9	N/A
2/29/2020	206	22	-110	37	N/A
11/30/2019	200	22	-59	49	N/A
8/31/2019	195	21	-31	30	N/A
5/31/2019	187	33	-21	43	N/A
2/28/2019	180	30	-17	30	N/A
11/30/2018	174	29	-11	23	N/A
8/31/2018	169	28	-9	26	N/A
5/31/2018	165	28	N/A	16	N/A
2/28/2018	161	28	N/A	22	N/A
11/30/2017	157	28	N/A	14	N/A
8/31/2017	152	26	N/A	10	N/A
5/31/2017	146	21	N/A	4	N/A
2/28/2017	140	20	N/A	12	N/A
11/30/2016	136	19	N/A	16	N/A
8/31/2016	131	18	N/A	25	N/A
2/29/2016	121	13	N/A	14	N/A
11/30/2015	116	13	N/A	18	N/A
8/31/2015	107	10	N/A	10	N/A
5/31/2015	103	10	N/A	11	N/A
2/28/2015	98	9	N/A	16	N/A
11/30/2014	94	7	N/A	13	N/A
8/31/2014	91	8	N/A	12	N/A
5/31/2014	86	6	N/A	12	N/A
2/28/2014	82	5	N/A	11	N/A
11/30/2013	78	3	N/A	11	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if TMCLIFE's forecast earnings growth is above the savings rate (3.6%).

Kazançlar ve Piyasa: Insufficient data to determine if TMCLIFE's earnings are forecast to grow faster than the MY market

Yüksek Büyüme Kazançları: Insufficient data to determine if TMCLIFE's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if TMCLIFE's revenue is forecast to grow faster than the MY market.

Yüksek Büyüme Geliri: Insufficient data to determine if TMCLIFE's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if TMCLIFE's Return on Equity is forecast to be high in 3 years time

TMC Life Sciences Berhad Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

TMC Life Sciences Berhad, Annual General Meeting, Nov 06, 2024

New minor risk - Dividend sustainability

Dividend of RM0.022 announced

Full year 2024 earnings released: EPS: RM0.023 (vs RM0.023 in FY 2023)

TMC Life Sciences Berhad Proposes Special Single-Tier Dividend for the Financial Year Ended June 30, 2024, Payable on January 3, 2025

Third quarter 2024 earnings released: EPS: RM0.006 (vs RM0.008 in 3Q 2023)

Second quarter 2024 earnings released: EPS: RM0.008 (vs RM0.003 in 2Q 2023)

TMC Life Sciences Berhad Announces Redesignation of Dr Heng Jun Li Melvin from Non Executive Director to Group Chief Executive Officer

First quarter 2024 earnings released: EPS: RM0.009 (vs RM0.004 in 1Q 2023)

TMC Life Sciences Berhad Announces Redesignation of Kan Kheong Ng as Executive Vice Chairman

TMC Life Sciences Berhad, Annual General Meeting, Nov 02, 2023

TMC Life Sciences Berhad Announces Single-Tier Final Dividend Per Ordinary Share for the Financial Year Ended 30 June 2023, Payable on 03 January 2024

Full year 2023 earnings released: EPS: RM0.023 (vs RM0.024 in FY 2022)

High number of new directors

Tmc Life Sciences Berhad Announces Appointment of Dato' Mohd Sheridan Bin Ramli as Independent and Non Executive Director

TMC Life Sciences Berhad Announces Redesignation of Cheah Ho Chee as Independent and Non Executive Chairman of Risk Committee

Third quarter 2023 earnings released: EPS: RM0.008 (vs RM0.004 in 3Q 2022)

TMC Life Sciences Berhad Announces Appointment of Puan Mazrina Binti Arifin as Independent and Non Executive Director

TMC Life Sciences Berhad (KLSE:TMCLIFE) Seems To Use Debt Quite Sensibly

Second quarter 2023 earnings released: EPS: RM0.003 (vs RM0.004 in 2Q 2022)

TMC Life Sciences Berhad Appoints Dr. Heng Jun Li Melvin as Non Independent and Non Executive Director

TMC Life Sciences Berhad Reports Write Offs for the Quarter Ended September 30, 2022

First quarter 2023 earnings released: EPS: RM0.004 (vs RM0.002 in 1Q 2022)

TMC Life Sciences Berhad Announces Appointment of June Leong Lai Ling as Independent and Non Executive Member of Audit Committee

TMC Life Sciences Berhad, Annual General Meeting, Nov 03, 2022

We Think TMC Life Sciences Berhad (KLSE:TMCLIFE) Can Stay On Top Of Its Debt

Full year 2022 earnings released: EPS: RM0.024 (vs RM0.012 in FY 2021)

Investors Met With Slowing Returns on Capital At TMC Life Sciences Berhad (KLSE:TMCLIFE)

TMC Life Sciences Berhad Proposes Single-Tier Final Dividend for the Financial Year Ended 30 June 2022, Payable on 03 January 2023

TMC Life Sciences Berhad Appoints Cheah Ho Chee as Independent and Non Executive Director

TMC Life Sciences Berhad Announces CFO Changes

Third quarter 2022 earnings released: EPS: RM0.004 (vs RM0.002 in 3Q 2021)

Insufficient new directors

Insufficient new directors

Insufficient new directors

TMC Life Sciences Berhad Announces Re-Designation of Wong Yu Chee as Group Chief Accounting Officer from Group Chief Financial Officer

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Director Lee George Lam has joined 10th company board

Full year 2021 earnings released: EPS RM0.012 (vs RM0.009 in FY 2020)

TMC Life Sciences Berhad (KLSE:TMCLIFE) Shareholders Will Want The ROCE Trajectory To Continue

New 90-day high: RM0.79

TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

New 90-day high: RM0.68

Returns On Capital - An Important Metric For TMC Life Sciences Berhad (KLSE:TMCLIFE)

TMC Life Sciences Berhad Announces Re-Designation of Dato' Sri Mohd Mokhtar Bin Mohd Shariff as Independent Non-Executive Chairman

New 90-day high: RM0.60

Would Shareholders Who Purchased TMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Three Years Be Happy With The Share price Today?

Should You Use TMC Life Sciences Berhad's (KLSE:TMCLIFE) Statutory Earnings To Analyse It?

New 90-day high: RM0.54

New 90-day low - RM0.48

Full year earnings released - EPS RM0.0091

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin